ABEONA THERAPEUTICS INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ABEONA THERAPEUTICS INC. (ABEO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.54 million as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-17
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.54M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.46M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.98M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $10.80M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $2.54M 10-K · filed 2026-03-17 |
| 2024-12-31 | $2.46M 10-K · filed 2026-03-17 |
| 2023-12-31 | $11.98M 10-K · filed 2025-03-20 |
| 2022-12-31 | $10.80M 10-K · filed 2024-03-18 |
| 2021-12-31 | $10.54M 10-K · filed 2023-03-29 |
| 2020-12-31 | $9.55M 10-K · filed 2022-03-31 |
| 2019-12-31 | $7.96M 10-K · filed 2021-03-24 |
| 2018-12-31 | $6.32M 10-K · filed 2020-03-16 |
| 2017-12-31 | $5.12M 10-K · filed 2019-03-18 |
| 2016-12-31 | $6.45M 10-K · filed 2018-03-16 |
| 2015-12-31 | $3.68M 10-K · filed 2017-03-30 |
| 2014-12-31 | $542.00K 10-K · filed 2016-03-30 |
| 2013-12-31 | $473.00K 10-K · filed 2015-03-31 |
| 2012-12-31 | $1.53M 10-K · filed 2014-03-26 |
| 2011-12-31 | $1.48M 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |